Advertisement

Correction to: Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study)

  • Hirokazu MurakamiEmail author
  • Tetsuhiro Kasamatsu
  • Jun Murakami
  • Toru Kiguchi
  • Takeshi Kanematsu
  • Daisuke Ogawa
  • Hiroyuki Takamatsu
  • Hiroshi Handa
  • Shuji Ozaki
  • Hirokazu Miki
  • Takeshi Takahashi
  • Takaaki Takeo
  • Tatsuya Yamauchi
  • Takanobu Morishita
  • Hiroshi Kosugi
  • Kazuyuki Shimizu
Correction
  • 110 Downloads

Correction to: International Journal of Hematology (2019) 109:409–417  https://doi.org/10.1007/s12185-019-02607-z

The authors would like to correct the errors in the publication of the original article. The correction details are given below:

The fifth sentence under the heading “Abstract” should read as “Median PFS was 4.4 months, 12.1 months, and 35.5 months in Groups A, B, and C, respectively, and was significantly prolonged in Group C than in Group A (p = 0.016).”.

The paragraphs under the heading “Efficacy” in “Results” section should read as below:

The median duration of the maintenance therapy with thalidomide was 13.2 months in whole cases, 13.2 months in Group B, and 14.2 months in Group C, respectively. The response to induction therapy was; complete response in 6 patients (17.6%), very good partial response in 12 patients (35.3%), partial response in 11 patients (32.3%), and stable disease in 5 patients (14.7%), respectively. There was no significant difference in the overall response rate (≥ PR) among Groups A (75.0%), B (91.7%), and C (90.0%). In the thalidomide maintenance groups (22 patients), there was an improvement in the depth of response during the maintenance therapy in 3 patients (13.6%; 2 in Group B and 1 in Group C), and a sustainment of response after induction therapy in 8 patients (36.4%). Progression of the disease occurred in 10 patients in Group A (83.3%), 8 patients in Group B (66.7%), and 4 patients in Group C (40%), respectively, during the maintenance phase, however, there was no significant difference between the 3 groups. The 2-year PFS rate was 25.0%, 33.3%, and 68.4% in Groups A, B, and C, respectively. Median PFS was 4.4 months, 12.1 months, and 35.5 months in Groups A, B, and C, respectively (Fig. 1a), and was significantly prolonged in Group C than in Group A (p = 0.016). There was no significant difference in median OS from the initiation of maintenance therapy between Groups A, B, and C (38.3 months, not reached, and 37.0 months, respectively) (Fig. 1b).

There was no significant difference in median PFS between the patients who received induction therapy with conventional chemotherapy-based regimen (11.2 months) and those who received novel agents-based regimen (12.4 months) (p = 0.859) (Fig. 2a). There was no significant difference in median PFS between newly-diagnosed patients (12.1 months) and relapsed patients (25.2 months) (p = 0.246) (Fig. 2b).

The second sentence under the heading “Discussion”, “The 2-year PFS rate from the initiation of maintenance therapy was significantly higher in Group C (100 mg cohort) than in Group A (no maintenance cohort) (p = 0.005).” should be deleted and the third sentence should read as “The median PFS was significantly prolonged in Group C (100 mg cohort) than in Group A (no maintenance cohort) (p = 0.016) (Fig. 1a), but there was no difference between the Groups B and A.”

In addition, revised Figs. 1 and 2 were given in this correction.
Fig. 1

Kaplan–Meier estimates for progression-free survival and overall survival according to study groups. a Progression-free survival curves for the non-maintenance group (median: 4.4 months), the 50 mg thalidomide maintenance group (median: 12.1 months), and the 100 mg thalidomide maintenance group (median: 35.5 months). b Overall survival curves for the non-maintenance group (median: 38.3 months), the 50 mg thalidomide maintenance group (median: not reached), and the 100 mg thalidomide maintenance group (median: 37.0 months)

Fig. 2

Kaplan–Meier estimates for progression-free survival according to induction therapy regimen and patient status. a Progression-free survival curves for patients treated with conventional chemotherapy-based regimen (median: 11.2 months) and those treated with novel agent-based regimen (median: 12.4 months). b Progression-free survival curves for newly diagnosed patients (median: 12.1 months) and relapsed patients (median: 25.2 months)

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Hirokazu Murakami
    • 1
    Email author
  • Tetsuhiro Kasamatsu
    • 1
  • Jun Murakami
    • 2
  • Toru Kiguchi
    • 3
  • Takeshi Kanematsu
    • 4
  • Daisuke Ogawa
    • 5
  • Hiroyuki Takamatsu
    • 6
  • Hiroshi Handa
    • 7
  • Shuji Ozaki
    • 8
  • Hirokazu Miki
    • 9
  • Takeshi Takahashi
    • 10
  • Takaaki Takeo
    • 11
  • Tatsuya Yamauchi
    • 12
  • Takanobu Morishita
    • 13
  • Hiroshi Kosugi
    • 14
  • Kazuyuki Shimizu
    • 15
  1. 1.Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashiJapan
  2. 2.Department of HematologyToyama University HospitalToyamaJapan
  3. 3.Department of HematologyChugoku Central HospitalFukuyamaJapan
  4. 4.Department of Clinical LaboratoryNagoya University HospitalNagoyaJapan
  5. 5.Department of HematologyNagasaki Prefectural Shimabara HospitalShimabaraJapan
  6. 6.Department of HematologyKanazawa University HospitalKanazawaJapan
  7. 7.Department of HematologyGunma UniversityMaebashiJapan
  8. 8.Department of HematologyTokushima Prefectural Central HospitalTokushimaJapan
  9. 9.Division of Transfusion Medicine and Cell TherapyTokushima University HospitalTokushimaJapan
  10. 10.Department of HematologyGifu Municipal HospitalGifuJapan
  11. 11.Department of HematologyYokkaichi Municipal HospitalYokkaichiJapan
  12. 12.Department of HematologyToki Municipal General HospitalTokiJapan
  13. 13.Department of HematologyJapanese Red Cross Nagoya Daiichi HospitalNagoyaJapan
  14. 14.Department of HematologyOgaki Municipal HospitalOgakiJapan
  15. 15.Department of Hematology/OncologyHigashi Nagoya National HospitalNagoyaJapan

Personalised recommendations